Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other financing activities (2020 - 2024)

Tarsus Pharmaceuticals (TARS) has 3 years of Other financing activities data on record, last reported at $39000.0 in Q3 2024.

  • For Q3 2024, Other financing activities changed N/A year-over-year to $39000.0; the TTM value through Dec 2025 reached $39000.0, changed 0.0%, while the annual FY2024 figure was $3.5 million, N/A changed from the prior year.
  • Other financing activities reached $39000.0 in Q3 2024 per TARS's latest filing, down from $60000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $2.1 million in Q4 2020 and bottomed at $1000.0 in Q2 2020.
  • Average Other financing activities over 3 years is $464857.1, with a median of $60000.0 recorded in 2022.